<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Shanghai Arch Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Shanghai Arch Psychiatry</journal-id><journal-id journal-id-type="publisher-id">SAP</journal-id><journal-title-group><journal-title>Shanghai Archives of Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">1002-0829</issn><publisher><publisher-name>Shanghai Municipal Bureau of Publishing</publisher-name><publisher-loc>Shanghai, China</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26120260</article-id><article-id pub-id-type="pmc">4466851</article-id><article-id pub-id-type="publisher-id">sap-27-02-103</article-id><article-id pub-id-type="doi">10.11919/j.issn.1002-0829.214151</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Research Article</subject></subj-group></article-categories><title-group><article-title>Efficacy and safety of the Chinese herbal medicine shuganjieyu with
and without adjunctive repetitive transcranial magnetic stimulation (rTMS) for
geriatric depression: a randomized controlled trial</article-title><trans-title-group xml:lang="zh"><trans-title>&#x04e2d;&#x08349;&#x0836f;&#x08212;&#x0809d;&#x089e3;&#x090c1;&#x080f6;&#x056ca;&#x05355;&#x07528;&#x06216;&#x08054;&#x05408;&#x091cd;&#x0590d;&#x07ecf;&#x09885;&#x078c1;&#x0523a;&#x06fc0;&#x0ff08;rTMS&#x0ff09;&#x06cbb;&#x07597;&#x08001;&#x05e74;&#x0671f;&#x06291;&#x090c1;&#x075c7;&#x07684;&#x07597;&#x06548;&#x0548c;&#x05b89;&#x05168;&#x06027;&#x0ff1a;&#x04e00;&#x09879;&#x0968f;&#x0673a;&#x05bf9;&#x07167;&#x07814;&#x07a76;</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name><surname>XIE</surname><given-names>Minmin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="bio" rid="d35e38">*</xref></contrib><contrib contrib-type="author"><name><surname>JIANG</surname><given-names>Wenhai</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="corresp" rid="cor1"/></contrib><contrib contrib-type="author"><name><surname>YANG</surname><given-names>Haibo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><aff id="aff1"><sup>1</sup>Daqing Campus of Harbin Medical University, Daqing,
Heilongjiang Province, China</aff><aff id="aff2"><sup>2</sup>The Third People&#x02019;s Hospital of Daqing, Daqing,
Heilongjiang Province, China</aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>correspondence: <email>dqjwh@126.com</email></corresp></author-notes><pub-date pub-type="ppub"><day>25</day><month>4</month><year>2015</year></pub-date><volume>27</volume><issue>2</issue><fpage>103</fpage><lpage>110</lpage><history><date date-type="received"><day>18</day><month>3</month><year>2015</year></date><date date-type="accepted"><day>09</day><month>4</month><year>2015</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015 by Shanghai Municipal Bureau of
Publishing</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/"><license-p>This work is licensed under a Creative Commons
Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy
of this license, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-sa/4.0/">http://creativecommons.org/licenses/by-nc-sa/4.0/</ext-link></license-p></license></permissions><abstract><sec id="s1"><title>Background</title><p>Pharmacological treatment of geriatric depression is often ineffective
because patients cannot tolerate adequate doses of antidepressant
medications. </p></sec><sec id="s2"><title>Aim</title><p>Examine the efficacy and safety of shuganjieyu &#x02013; the first Chinese herbal
medicine approved for the treatment of depression by China&#x02019;s drug regulatory
agency -- with and without adjunctive treatment with repetitive transcranial
magnetic stimulation (rTMS) in the treatment of geriatric depression.</p></sec><sec id="s3"><title>Methods</title><p>Sixty-five inpatients 60 or older who met ICD-10 criteria for depression were
randomly assigned to an experimental group (shuganjieyu + rTMS) (n=36) or a
control group (shuganjieyu + sham rTMS)(n=29). All participants received 4
capsules of shuganjieyu daily for 6 weeks. rTMS (or sham rTMS) was
administered 20 minutes daily, five days a week for 4 weeks. Blinded raters
used the Hamilton Rating Scale for Depression (HAMD-17) and the Treatment
Emergent Symptom Scale to assess clinical efficacy and safety at baseline
and 1, 2, 4, and 6 weeks after starting treatment. Over the six-week trial,
there was only one dropout from the experimental group and two dropouts from
the control group.</p></sec><sec id="s4"><title>Results</title><p>None of the patients had serious side effects, but 40% in the experimental
group and 50% in the control group experienced minor side effects that all
resolved spontaneously. Both groups showed substantial stepwise improvement
in depressive symptoms over the 6 weeks. Repeated measures ANOVA found no
differences between the two groups. After 6 weeks, 97% of the experimental
group had experienced a 25% or greater drop in the level of depression, but
only 20% had experience a 50% or greater drop in the level of depression;
the corresponding values in the control group were 96% and 19%. There were
some minor, non-significant differences in the onset of the treatment effect
between the different types of depressive symptoms, but by the second week
of treatment all five HAMD-17 subscale scores had improved significantly in
both groups</p></sec><sec id="s5"><title>Conclusion</title><p>The Chinese herbal medicine shuganjieyu is effective and safe in the
treatment of geriatric depression, but only a minority of patients have
greater than 50% improvement in their depressive symptoms after 6 weeks of
treatment. Adjunctive use of rTMS with shuganjieyu does not improve the
overall outcome and does not significantly speed up the onset of action of
shuganjieyu. </p></sec></abstract><trans-abstract xml:lang="zh"><sec><title>&#x080cc;&#x0666f;</title><p>&#x07531;&#x04e8e;&#x08001;&#x05e74;&#x0671f;&#x06291;&#x090c1;&#x075c7;&#x060a3;&#x08005;&#x05f80;&#x05f80;&#x04e0d;&#x080fd;&#x08010;&#x053d7;&#x08db3;&#x091cf;&#x07684;&#x06297;&#x06291;&#x090c1;&#x0836f;&#x07269;&#x0ff0c;&#x06240;&#x04ee5;&#x0836f;&#x07269;&#x06cbb;&#x07597;&#x08001;&#x05e74;&#x06291;&#x090c1;&#x075c7;&#x07684;&#x07597;&#x06548;&#x04e0d;&#x04f73;&#x03002;</p></sec><sec><title>&#x076ee;&#x07684;</title><p>&#x063a2;&#x08ba8;&#x08212;&#x0809d;&#x089e3;&#x090c1;&#x080f6;&#x056ca;&#x0ff08;&#x04e2d;&#x056fd;&#x0836f;&#x054c1;&#x076d1;&#x07763;&#x07ba1;&#x07406;&#x090e8;&#x095e8;&#x06279;&#x051c6;&#x07528;&#x04e8e;&#x06cbb;&#x07597;&#x06291;&#x090c1;&#x075c7;&#x07684;&#x09996;&#x04e2a;&#x04e2d;&#x08349;&#x0836f;&#x0ff09;&#x05355;&#x07528;&#x06216;&#x08054;&#x05408;&#x091cd;&#x0590d;&#x07ecf;&#x09885;&#x078c1;&#x0523a;&#x06fc0;&#x0ff08;repetitive transcranial
magnetic stimulation&#x0ff0c;rTMS&#x0ff09;&#x06cbb;&#x07597;&#x08001;&#x05e74;&#x0671f;&#x06291;&#x090c1;&#x075c7;&#x07684;&#x07597;&#x06548;&#x0548c;&#x05b89;&#x05168;&#x06027;&#x03002;</p></sec><sec><title>&#x065b9;&#x06cd5;</title><p>&#x05c06;65&#x04f8b;60&#x05c81;&#x04ee5;&#x04e0a;&#x07b26;&#x05408;ICD-10&#x08bca;&#x065ad;&#x06807;&#x051c6;&#x07684;&#x06291;&#x090c1;&#x075c7;&#x04f4f;&#x09662;&#x060a3;&#x08005;&#x0968f;&#x0673a;&#x05206;&#x04e3a;&#x07814;&#x07a76;&#x07ec4;&#x0ff08;&#x08212;&#x0809d;&#x089e3;&#x090c1;&#x080f6;&#x056ca;+rTMS&#x0ff09;&#x0ff08;n=36&#x0ff09;&#x0548c;&#x05bf9;&#x07167;&#x07ec4;&#x0ff08;&#x08212;&#x0809d;&#x089e3;&#x090c1;&#x080f6;&#x056ca;+&#x04f2a;rTMS&#x0ff09;&#x0ff08;n=29&#x0ff09;&#x03002;&#x06240;&#x06709;&#x060a3;&#x08005;&#x06bcf;&#x065e5;&#x0670d;&#x07528;4&#x07c92;&#x08212;&#x0809d;&#x089e3;&#x090c1;&#x080f6;&#x056ca;&#x0ff0c;&#x04e00;&#x05171;&#x0670d;&#x07528;6&#x05468;&#x03002;rTMS&#x0ff08;&#x06216;&#x04f2a;rTMS&#x0ff09;&#x06cbb;
&#x07597;20 min/d&#x0ff0c;&#x06bcf; &#x05468;5
d&#x0ff0c;&#x05171;4&#x05468;&#x03002;&#x08bc4;&#x04f30;&#x08005;&#x05728;&#x04e0d;&#x077e5;&#x060a3;&#x08005;&#x05206;&#x07ec4;&#x060c5;&#x051b5;&#x04e0b;&#x0ff0c;&#x091c7;&#x07528;&#x06c49;&#x05bc6;&#x05c14;&#x0987f;&#x06291;&#x090c1;&#x091cf;&#x08868;&#x0ff08;HAMD-17&#x0ff09;&#x0548c;&#x0526f;&#x053cd;&#x05e94;&#x091cf;&#x08868;&#x08bc4;&#x04f30;&#x057fa;&#x07ebf;&#x0548c;&#x06cbb;&#x07597;&#x05f00;&#x059cb;&#x0540e;1&#x03001;2&#x03001;4&#x03001;6&#x05468;&#x07684;&#x05e8a;&#x07597;&#x06548;&#x0548c;&#x05b89;&#x05168;&#x06027;&#x03002;&#x05728;6&#x05468;&#x07684;&#x07814;&#x07a76;&#x08fc7;&#x07a0b;&#x04e2d;&#x0ff0c;&#x07814;&#x07a76;&#x07ec4;&#x04ec5;&#x06709;1&#x04eba;&#x08131;&#x0843d;&#x0ff0c;&#x05bf9;&#x07167;&#x07ec4;&#x04ec5;&#x06709;2&#x04eba;&#x08131;&#x0843d;&#x03002;</p></sec><sec><title>&#x07ed3;&#x0679c;</title><p>&#x06ca1;&#x06709;&#x04e00;&#x04f8b;&#x060a3;&#x08005;&#x051fa;&#x073b0;&#x04e25;&#x091cd;&#x04e0d;&#x0826f;&#x053cd;&#x05e94;&#x0ff0c;&#x04f46;&#x07814;&#x07a76;&#x07ec4;&#x0548c;&#x05bf9;&#x07167;&#x07ec4;&#x04e2d;&#x05206;&#x0522b;&#x06709;40&#x0ff05;&#x0548c;50&#x0ff05;&#x07684;&#x060a3;&#x08005;&#x051fa;&#x073b0;&#x08f7b;&#x05fae;&#x07684;&#x04e0d;&#x0826f;&#x053cd;&#x05e94;&#x0ff0c;&#x05747;&#x081ea;&#x0884c;&#x07f13;&#x089e3;&#x03002;&#x04e24;&#x07ec4;&#x07684;&#x06291;&#x090c1;&#x075c7;&#x072b6;&#x05728;6&#x05468;&#x05185;&#x05747;&#x09010;&#x06b65;&#x0660e;&#x0663e;&#x06539;&#x05584;&#x03002;&#x091cd;&#x0590d;&#x06d4b;&#x091cf;&#x065b9;&#x05dee;&#x05206;&#x06790;&#x06ca1;&#x06709;&#x053d1;&#x073b0;&#x04e24;&#x07ec4;&#x04e4b;&#x095f4;&#x06709;&#x0663e;&#x08457;&#x05dee;&#x05f02;&#x03002;6&#x05468;&#x0540e;&#x0ff0c;&#x07814;&#x07a76;&#x07ec4;97&#x0ff05;&#x07684;&#x060a3;&#x08005;&#x06291;&#x090c1;&#x07a0b;&#x05ea6;&#x04e0b;&#x0964d;&#x05e45;&#x05ea6;&#x05927;&#x04e8e;&#x07b49;&#x04e8e;25&#x0ff05;&#x0ff0c;&#x04f46;&#x053ea;&#x06709;20&#x0ff05;&#x08005;&#x07684;&#x04e0b;&#x0964d;&#x05e45;&#x05ea6;&#x05927;&#x04e8e;&#x07b49;&#x04e8e;50&#x0ff05;&#x0ff1b;&#x05bf9;&#x07167;&#x07ec4;&#x04e2d;&#x076f8;&#x05e94;&#x07684;&#x060a3;&#x08005;&#x06bd4;&#x04f8b;&#x05206;&#x0522b;&#x04e3a;96&#x0ff05;&#x0548c;19&#x0ff05;&#x03002;&#x0867d;&#x07136;&#x04e0d;&#x0540c;&#x07684;&#x06291;&#x090c1;&#x075c7;&#x072b6;&#x04e4b;&#x095f4;&#x06cbb;&#x07597;&#x08d77;&#x06548;&#x06709;&#x07740;&#x08f7b;&#x05fae;&#x07684;&#x03001;&#x0975e;&#x0663e;&#x08457;&#x06027;&#x07684;&#x05dee;&#x05f02;&#x0ff0c;&#x04f46;&#x0662f;&#x06cbb;&#x07597;&#x07b2c;&#x04e8c;&#x05468;&#x0540e;&#x04e24;&#x07ec4;HAMD-17&#x04e94;&#x04e2a;&#x05206;&#x091cf;&#x08868;&#x07684;&#x08bc4;&#x05206;&#x05747;&#x0663e;&#x08457;&#x06539;&#x05584;&#x03002;</p></sec><sec><title>&#x07ed3;&#x08bba;</title><p>&#x04e2d;&#x08349;&#x0836f;&#x08212;&#x0809d;&#x089e3;&#x090c1;&#x080f6;&#x056ca;&#x06cbb;&#x07597;&#x08001;&#x05e74;&#x06291;&#x090c1;&#x075c7;&#x0662f;&#x06709;&#x06548;&#x0548c;&#x05b89;&#x05168;&#x07684;&#x0ff0c;&#x07136;&#x0800c;&#x053ea;&#x06709;&#x05c11;&#x06570;&#x060a3;&#x08005;&#x07684;&#x06291;&#x090c1;&#x075c7;&#x072b6;&#x05728;&#x06cbb;&#x07597;6&#x05468;&#x0540e;&#x06539;&#x05584;&#x07a0b;&#x05ea6;&#x05927;&#x04e8e;50&#x0ff05;&#x03002;&#x08054;&#x05408;&#x091cd;&#x0590d;&#x07ecf;&#x09885;&#x078c1;&#x0523a;&#x06fc0;&#x06cbb;&#x07597;&#x05e76;&#x06ca1;&#x06709;&#x0589e;&#x052a0;&#x08212;&#x0809d;&#x089e3;&#x090c1;&#x080f6;&#x056ca;&#x07684;&#x0603b;&#x04f53;&#x07597;&#x06548;&#x0ff0c;&#x04e5f;&#x06ca1;&#x06709;&#x0663e;&#x08457;&#x052a0;&#x05feb;&#x0540e;&#x08005;&#x07684;&#x08d77;&#x06548;&#x03002;</p></sec><sec><title>&#x04e2d;&#x06587;&#x05168;&#x06587;</title><p>&#x0672c;&#x06587;&#x05168;&#x06587;&#x04e2d;&#x06587;&#x07248;&#x04ece;2015&#x05e74;6&#x06708;6&#x065e5;&#x08d77;&#x05728;<ext-link ext-link-type="uri" xlink:href="http://dx.doi.org/10.11919/j.issn.1002-0829.214151">http://dx.doi.org/10.11919/j.issn.1002-0829.214151</ext-link>&#x053ef;&#x04f9b;&#x0514d;&#x08d39;&#x09605;&#x089c8;&#x04e0b;&#x08f7d;</p></sec></trans-abstract><kwd-group kwd-group-type="author-created"><kwd>shuganjieyu</kwd><kwd>Chinese herbal medicine</kwd><kwd>repetitive transcranial magnetic stimulation</kwd><kwd>geriatric depression</kwd><kwd>China</kwd></kwd-group><funding-group><funding-statement>The authors obtained no funding to support this
study.</funding-statement></funding-group></article-meta></front><body><sec id="s6"><label>1.</label><title>Background</title><p> Depression is a common mental disorder and a leading cause of disease burden in the
elderly population. According to data from the World Health Organization, the
prevalence of depression in elderly individuals is between 3 and 10%.<xref rid="B1" ref-type="bibr">[1]</xref> Geriatric depression usually refers to
depression among individuals 60 years of age or older.<xref rid="B2" ref-type="bibr">[2]</xref> Slow onset and atypical symptoms (e.g., relatively mild depressive
symptoms and frequent concurrent somatic symptoms) are common in geriatric
depression, which makes it easy to overlook. Failure to identify and treat geriatric
depression can exacerbate the decline in physical functioning due to concurrent
physical illnesses, increase the level of disability, and, thus, substantially
decrease the individual&#x02019;s quality of life.<xref rid="B3" ref-type="bibr">[3]</xref></p><p> Using a selective serotonin re-uptake inhibitor (SSRI) is the recommended first-line
treatment for geriatric depression in most high-income countries. But these
medications have many side-effects &#x02013; some of which are serious<xref rid="B4" ref-type="bibr">[4]</xref> &#x02013; that increase in prevalence and severity with increased
dosage and that may be more prevalent and less tolerated in elderly individuals. The
initial dose of antidepressant medication used for geriatric depression is usually
relatively low due to clinicians&#x02019; concerns about serious side effects or
interactions with other medications being used for physical illnesses. Partly due to
this reason (i.e., using sub-optimal dosages), the treatment effect of common
antidepressants in geriatric depression is not as robust as that in younger adults;
moreover, geriatric patients who consider the medications less effective are often
non-compliant with anti-depressant treatment. Many of these untreated or
inadequately treated individuals become chronically depressed.</p><p> Chinese herbal medicines have been widely used in the treatment of depression.
Shuganjieyu, which is composed of St. John&#x02019;s wort and extracts of Siberian ginseng,
is the first Chinese herb-based medication approved by the Chinese drug regulatory
agency (CFDA) for the treatment of depression (approved in 2008). It has been shown
to be effective, safe, and well tolerated.[<xref rid="B5" ref-type="bibr">5</xref>-<xref rid="B7" ref-type="bibr">7</xref>] The main ingredients of
shuganjieyu are hypericum perforatum and acanthopanax extract. The antidepressant
effect of hypericum perforatum, which has a mechanism of action similar to that of
SSRIs, has been well recognized.<xref rid="B8" ref-type="bibr">[8]</xref> Repetitive
transcranial magnetic stimulation (rTMS) is a non-invasive intervention that has
also been shown to be a safe and effective treatment for depression in China and
abroad.[<xref rid="B9" ref-type="bibr">9</xref>-<xref rid="B11" ref-type="bibr">11</xref>] This study aims to evaluate the efficacy and safety of shuganjieyu
for geriatric depression when used with or without adjunctive treatment with
rTMS.</p></sec><sec sec-type="methods" id="s7"><label>2.</label><title>Methods</title><sec id="s7a"><label>2.1</label><title>Sample</title><p> Figure 1 shows the enrollment of subjects in the study. Study participants were
65 patients with geriatric depression admitted to the Third Hospital of Daqing
Municipality between December 2013 and September 2014. The inclusion criteria
were as follows. (a) Met the diagnostic criteria for depression according to the
10<sup>th</sup> edition of the International Classification of Diseases
(ICD-10)<xref rid="B12" ref-type="bibr">[12]</xref> and had not been taking
antidepressants in the two weeks prior to enrollment. (b) Met the classification
of &#x02018;liver stagnation and spleen deficiency&#x02019; based on Traditional Chinese
Medicine theories.<xref rid="B13" ref-type="bibr">[13]</xref> [Symptoms of
stagnated liver energy (&#x02018;qi&#x02019;) include uncoordinated mood and will, lack of
aspiration, and low mood; symptoms of spleen deficiency include emotional
distress, restlessness, poor memory, insomnia, dizziness and poor appetite.] (c)
Aged 60 years or older. (d) Scored no less than 18 points on the 17-item version
of the Hamilton Rating Scale for Depression (HAMD-17).<xref rid="B14" ref-type="bibr">[14]</xref> (e) Were willing to participate and signed the
informed consent form (or their guardian signed the consent form). (f) Were in
good physical health based on the baseline physical examination,
electrocardiogram (EKG), clinical laboratory test results, and medical history.
Exclusion criteria included (a) having suicidal tendencies; (b) the presence of
serious heart, liver, or kidney dysfunction or any disease of the endocrine
system; (c) had a history of epilepsy; (d) had a history of psychoactive
substance dependence (including alcohol); (e) had depression induced by other
mental or physical conditions; (f) had a bipolar disorder; (g) were unfit for
rTMS treatment; (h) were allergic to hypericum perforatum or acanthopanax; (i)
had abnormal EKG or laboratory test results; (j) had a history of poor
medication compliance; or (k) had received electroconvulsive therapy in the
month prior to enrollment. </p><fig id="sap-27-02-103-g002.tif" orientation="landscape" position="float"><label>Figure 1.</label><caption><title>Flowchart of the study</title></caption><graphic xlink:href="sap-27-02-103-g002"/></fig></sec><sec id="s7b"><label>2.2</label><title>Intervention</title><p> Patients who met the inclusion criteria were randomly assigned to the experiment
or control group using a random number table. Shuganjieyu provided by Chengdu
Kanghong Pharmaceuticals Co. Ltd., (China SFDA No. Z20080580) were used in the
study. Patients in both groups received two capsules of shuganjieyu immediately
after meals, twice a day for six weeks. Participants in the experiment group
were also treated with rTMS (using equipment from the Magstim Co., Ltd, UK) with
the coil located above the left dorsolateral prefrontal cortex; participants in
the control group were given mock-rTMS in which the coil touched the scalp but
no stimulation was provided. The rTMS stimulation was of low intensity (30% MT)
and low frequency (10HZ). Each session lasted for an average of 20 minutes. A
total of 20 rTMS sessions were administered in four 5-day cycles with 2-day
breaks between cycles. All participants and evaluators were masked during the
trial. For patients who experienced sleep problems during the treatment,
zopiclone or benzodiazepines were allowed for short-term treatment. </p></sec><sec id="s7c"><label>2.3</label><title>Assessment of efficacy</title><p> The Hamilton Rating Scale for Depression-17 Item (HAMD-17) was used to assess
efficacy and the Treatment Emergent Symptom Scale (TESS) was used to assess
safety.<xref rid="B14" ref-type="bibr">[14]</xref> The two scales were
administered at 1 week, 2 weeks, 4 weeks, and 6 weeks after the initiation of
the treatment. The reported inter-rater reliability of the Chinese version of
HAMD-17, based on the correlation of total scores between independent raters, is
between 0.88 and 0.99 and its validity, based on the correlation or the total
score and clinical ratings of the severity of depression, is 0.92.<xref rid="B15" ref-type="bibr">[15]</xref> Two trained associate senior
clinicians conducted these evaluations in this study; the inter-relater
reliability of their HAMD-17 total was good (Kappa 0.75 to 0.86). Routine blood
tests, tests of liver and kidney function, and EKGs were also assessed at the
same time periods. </p><p> The main measure of efficacy was the percent reduction from baseline HAMD-17
scores ([pretreatment score - post-treatment score]/pretreatment score x 100%)
at the end of the trial. Efficacy was categorized into remitted (reduction &#x0003e;75%
or total HAMD-17 score &#x0003c;7), significantly improved (reduction=50 to 74%),
improved (reduction=25 to 49%), and not improved (reduction &#x0003c;25%). </p><p> The HAMD-17 can be divided into 5 subscales:[<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref>] (a) 4 items in the
retardation subscale assess depressed mood, work and activities, psychomotor
retardation, and loss of sexual interest; (b) 3 items assess guilt, suicidal
ideation, and psychomotor agitation; (c) 3 items assess sleep problems including
difficulty of falling asleep, light sleep, and early awakening; (d) 6 items
assess anxiety and somatic symptoms including mental anxiety, somatic anxiety,
gastrointestinal symptoms, hypochondriasis, insight, and general somatic
symptoms. And (e) 1 item assesses loss of weight.</p></sec><sec id="s7d"><label>2.4</label><title>Statistical analysis</title><p> SPSS 19.0 was used for data analysis. Means and standard deviations were
provided. ANCOVA and repeated measures ANOVA (for HAMD-17 scores) were used to
compare differences over time and cross groups. Two-sample t-test was used to
compare cross-group differences and one-sample t-test was used to assess
within-group differences (i.e., compared to baseline). Chi-squared test was used
to compare categorical variables and Mann-Whitney rank test was use to compare
continuous variables that were not normally distributed.</p></sec></sec><sec id="s8"><label>3.</label><title>Results</title><sec id="s8a"><label>3.1</label><title>Characteristics of participants</title><p> Figure 1 shows the flowchart for the study. A total of 65 patients met the
inclusion criteria, among whom 36 were assigned to the experiment group and 29
to the control group. In the experiment group, 1 patient dropped out from the
study due to early hospital discharge; in the control group the diagnosis was
changed to schizophrenia 1 week after admission in 1 patient and another 2
patients dropped out of the study because of early hospital discharge.
Therefore, the final analysis included 35 individuals in the experiment group
and 26 in the control group. The study completion rate was 97.2% (35/36) in the
experimental group and 89.7% (26/29) in the control group. Table 1 shows the
characteristics of the individuals who completed the 6-week study; there are no
significant differences in gender, age, duration or illness or baseline total
HAMD-17 total score between the two groups. </p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Characteristics of study participants </p></caption><table frame="hsides" rules="groups" style="border-top:#000 1px solid;border-bottom:#000 1px solid;"><thead><tr><th align="left" rowspan="1" colspan="1">characteristic</th><th align="left" rowspan="1" colspan="1">experimental group<break/>(n=35)</th><th align="left" rowspan="1" colspan="1">control group<break/>(n=26)</th><th align="left" rowspan="1" colspan="1">statistic (p-value)</th></tr></thead><tbody><tr style="border-top:#000 1px solid;"><th align="left" colspan="4" rowspan="1">Gender</th></tr><tr><td align="left" rowspan="1" colspan="1">male, n (%) </td><td align="left" rowspan="1" colspan="1">12 (34.3%) </td><td align="left" rowspan="1" colspan="1">8 (30.8%) </td><td align="left" rowspan="1" colspan="1"><italic>&#x003c7;</italic><sup>2</sup>=0.08 (0.772)</td></tr><tr><td align="left" rowspan="1" colspan="1">female, n (%) </td><td align="left" rowspan="1" colspan="1">23 (63.7%)</td><td align="left" rowspan="1" colspan="1"> 18 (69.2%)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><th align="left" colspan="4" rowspan="1">Age in years</th></tr><tr><td align="left" rowspan="1" colspan="1">range </td><td align="left" rowspan="1" colspan="1">60-78 </td><td align="left" rowspan="1" colspan="1">60-76 </td><td align="left" rowspan="1" colspan="1"><italic>F</italic>=1.42 (0.237)</td></tr><tr><td align="left" rowspan="1" colspan="1">mean (sd) </td><td align="left" rowspan="1" colspan="1">65.3 (5.1) </td><td align="left" rowspan="1" colspan="1">64.7 (4.2)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><th align="left" colspan="4" rowspan="1">Months duration of illness</th></tr><tr><td align="left" rowspan="1" colspan="1">range </td><td align="left" rowspan="1" colspan="1">1-360 </td><td align="left" rowspan="1" colspan="1">1-240 </td><td align="left" rowspan="1" colspan="1"><italic>Z</italic>=0.044 (0.965)</td></tr><tr><td align="left" rowspan="1" colspan="1">median (IQR) </td><td align="left" rowspan="1" colspan="1">60 (24,156)</td><td align="left" rowspan="1" colspan="1"> 90 (21, 120)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr><tr><th align="left" colspan="4" rowspan="1">Baseline HAMD-17 score</th></tr><tr><td align="left" rowspan="1" colspan="1">range </td><td align="left" rowspan="1" colspan="1">18-29 </td><td align="left" rowspan="1" colspan="1">18-25 </td><td align="left" rowspan="1" colspan="1"><italic>F</italic>=0.20 (0.653)</td></tr><tr><td align="left" rowspan="1" colspan="1">mean (sd) </td><td align="left" rowspan="1" colspan="1">21.11 (2.93) </td><td align="left" rowspan="1" colspan="1">20.62 (2.610)</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td></tr></tbody></table><table-wrap-foot><fn><p>HAMD-17, 17-item version of the Hamilton Rating Scale for
Depression</p><p>IQR, interquartile range</p></fn></table-wrap-foot></table-wrap></sec><sec id="s8b"><label>3.2</label><title>Comparison of efficacy</title><p> As shown in Table 2, based on the results of the repeated measures ANOVA, there
were no significant cross-group differences (<italic>F</italic>=0.46,
<italic>p</italic>=0.502) or differences in group-time interaction
(<italic>F</italic>=1.07, <italic>p</italic>=0.352) in HAMD-17 total scores.
However, HAMD-17 scores changed significantly over time
(<italic>F</italic>=395.91, <italic>p</italic>&#x0003c;0.001). There was a gradual
decrease in the measured severity of depressive symptoms over the six weeks of
treatment that was similar in the two groups; by the end of the 6 weeks the mean
HAMD-17 score in both groups had dropped by more than 37%.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2.</label><caption><p>Comparison of mean (sd) Hamilton Depression Rating Scale (HAMD-17) scores
and the percent change in the scores from baseline during the 6 weeks of
treatment in the experimental and control groups<sup>a</sup></p></caption><table frame="hsides" rules="groups" style="border-top:#000 1px solid;border-bottom:#000 1px solid;"><thead><tr><td align="left" rowspan="1" colspan="1"><bold>group</bold></td><td align="center" rowspan="1" colspan="1"><bold>baseline</bold><break/>mean (sd)</td><td align="center" rowspan="1" colspan="1"><bold>1 week</bold><break/>mean (sd)<break/>[%
change]</td><td align="center" rowspan="1" colspan="1"><bold>2 weeks</bold><break/>mean (sd) <break/>[%
change]</td><td align="center" rowspan="1" colspan="1"><bold>4 weeks</bold><break/>mean (sd) <break/>[%
change]</td><td align="center" rowspan="1" colspan="1"><bold>6 weeks</bold><break/>mean (sd) <break/>[%
change]</td></tr></thead><tbody><tr style="border-top:#000 1px solid;"><td align="left" rowspan="1" colspan="1">experimental group<break/>(n=35)</td><td align="center" rowspan="1" colspan="1">21.11 (2.93)</td><td align="center" rowspan="1" colspan="1">19.60 (2.93)<sup>b</sup><break/>[-7.2%]</td><td align="center" rowspan="1" colspan="1">17.43 (2.87)<sup>b</sup><break/>[-17.4%]</td><td align="center" rowspan="1" colspan="1">14.57 (3.24)<sup>b</sup><break/>[-31.0%]</td><td align="center" rowspan="1" colspan="1">13.06 (3.30)<sup>b</sup><break/>[-38.1%]</td></tr><tr><td align="left" rowspan="1" colspan="1">control group <break/>(n=26)</td><td align="center" rowspan="1" colspan="1">20.62 (2.61)</td><td align="center" rowspan="1" colspan="1">18.77 (2.67)<break/>[-9.0%]</td><td align="center" rowspan="1" colspan="1">16.65 (2.71)<sup>b</sup><break/>[-19.3%]</td><td align="center" rowspan="1" colspan="1">14.35 (3.07)<sup>b</sup><break/>[-30.4%]</td><td align="center" rowspan="1" colspan="1">13.00 (2.91)<sup>b</sup><break/>[-37.0%]</td></tr><tr><td align="left" rowspan="1" colspan="1">comparison of groups<break/>F-value (p-value)</td><td align="center" rowspan="1" colspan="1">0.47 (0.494)</td><td align="center" rowspan="1" colspan="1"> 1.29 (0.261)</td><td align="center" rowspan="1" colspan="1"> 1.14 (0.291) </td><td align="center" rowspan="1" colspan="1">0.08 (0.785) </td><td align="center" rowspan="1" colspan="1">0.01 (0.944)</td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> repeated measures ANOVA found a significant difference
over time (<italic>F</italic><sub>time</sub>=395.94,
<italic>p</italic>&#x0003c;0.001), no significant difference by
treatment group (<italic>F</italic><sub>group</sub>=0.46,
<italic>p</italic>=0.502), and no significant interaction
between treatment group and time (<italic>F</italic><sub>group x
time</sub>=1.07, <italic>p</italic>=0.352)</p><p><sup>b</sup> comparison with baseline using two-sample t-test is
statistically significant (<italic>p</italic>&#x0003c;0.001)</p></fn></table-wrap-foot></table-wrap><p> At the end of the trial (after 6 weeks of treatment), the two groups had similar
efficacy. Using the classification system described in the methods section based
on the percent change in the baseline HAMD 17 score, among the 35 patients in
the experimental group who completed the 6 weeks of treatment, 1 had fully
remitted, 6 were significantly improved, 27 were improved, and 1 was unchanged;
thus the overall efficacy was 97.1% (34/35). Among the 26 patients in the
control group who completed the treatment, 1 had fully remitted, 4 were
significantly improved, 20 were improved, and 1 was unchanged; thus the overall
efficacy was 96.2% (25/26). However, among the 61 patients from both groups who
completed 6 weeks of treatment, only 2 (3.3%) remitted and only a further 10
(16.4%) had significant improvement; the remaining 80.3% (49/61) had less than
50% reduction in their baseline HAMD-17 scores. That is, by the end of the trial
only 20% (7/35) of experimental groups subjects and 19% (5/26) of control groups
subjects had experienced significant improvement (or remission) of their
depressive symptoms.</p><p> Table 3 presents comparisons of the five HAMD-17 subscale scores. All of the
subscales showed a dramatic drop in the mean scores over the 6 weeks of the
trial, but there were no significant differences between the experimental and
control groups in the magnitude or pace of the improvement. There were some
minor differences in the rate of improvement for the five subscales: after 1
week of treatment, the improvement in sleep and anxiety/somatic symptoms had
already become statistically significant, the improvement in weight loss was
only significant in the control group, the improvement in the &#x02018;guilt, suicidal
ideation, and agitation&#x02019; subscale was only significant in the experimental
group, and neither of the groups showed statistically significant improvement in
psychomotor retardation. However, by the end of the second week of treatment
both groups showed statistically significant improvement over baseline in all
five HAMD-17 subscales scores. </p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3.</label><caption><p>Comparison of mean (sd) factors scores of Hamilton Depression Rating
Scale (HAMD-17) before and after treatment in the experimental and
control groups<sup>a</sup></p></caption><table frame="hsides" rules="groups" style="border-top:#000 1px solid;border-bottom:#000 1px solid;"><thead><tr><th align="left" rowspan="1" colspan="1">factor</th><th align="center" rowspan="1" colspan="1">group</th><th align="center" rowspan="1" colspan="1"> baseline</th><th align="center" rowspan="1" colspan="1">1 week</th><th align="center" rowspan="1" colspan="1"> 2 weeks </th><th align="center" rowspan="1" colspan="1">4 weeks </th><th align="center" rowspan="1" colspan="1">6 weeks </th><th align="center" rowspan="1" colspan="1"><italic>F</italic><sub>time</sub></th><th align="center" rowspan="1" colspan="1"><italic>p</italic></th></tr></thead><tbody><tr style="border-top:#000 1px solid;"><td align="left" rowspan="2" colspan="1">retardation</td><td align="center" rowspan="1" colspan="1">experimental </td><td align="center" rowspan="1" colspan="1">6.74 (1.17)</td><td align="center" rowspan="1" colspan="1"> 6.66 (1.21) </td><td align="center" rowspan="1" colspan="1">6.29 (1.23)<sup>c</sup></td><td align="center" rowspan="1" colspan="1">5.34 (1.21)<sup>c</sup></td><td align="center" rowspan="1" colspan="1">4.89 (1.13)<sup>c</sup></td><td align="center" rowspan="2" colspan="1">97.18</td><td align="center" rowspan="2" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">control </td><td align="center" rowspan="1" colspan="1">6.62 (1.84) </td><td align="center" rowspan="1" colspan="1">6.50 (1.79) </td><td align="center" rowspan="1" colspan="1">5.81 (1.42)<sup>c</sup></td><td align="center" rowspan="1" colspan="1">5.27 (1.54)<sup>c</sup></td><td align="center" rowspan="1" colspan="1">4.65 (1.38)<sup>c</sup></td></tr><tr><td style="background: lightgrey" align="left" rowspan="2" colspan="1">guilt,
suicidal ideation,<break/>and agitation</td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">experimental </td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">2.31 (1.53) </td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">2.06
(1.33)<sup>b</sup></td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">1.83
(1.22)<sup>b</sup></td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">1.49
(1.27)<sup>c</sup></td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">1.23
(1.03)<sup>c</sup></td><td style="background: lightgrey" align="center" rowspan="2" colspan="1">39.76</td><td style="background: lightgrey" align="center" rowspan="2" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td style="background: lightgrey" align="left" rowspan="1" colspan="1">control </td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">2.42 (1.27)</td><td style="background: lightgrey" align="center" rowspan="1" colspan="1"> 2.19 (1.13) </td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">1.96
(1.11)<sup>b</sup></td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">1.54
(0.95)<sup>c</sup></td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">1.35
(1.02)<sup>c</sup></td></tr><tr><td align="left" rowspan="2" colspan="1">sleep problems</td><td align="center" rowspan="1" colspan="1">experimental </td><td align="center" rowspan="1" colspan="1">4.40 (1.22) </td><td align="center" rowspan="1" colspan="1">3.63 (1.35)<sup>c</sup></td><td align="center" rowspan="1" colspan="1">3.09 (1.10)<sup>c</sup></td><td align="center" rowspan="1" colspan="1">2.34 (1.16)<sup>c</sup></td><td align="center" rowspan="1" colspan="1">2.23 (1.17)<sup>c</sup></td><td align="center" rowspan="2" colspan="1">129.33</td><td align="center" rowspan="2" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">control </td><td align="center" rowspan="1" colspan="1">4.31 (0.97) </td><td align="center" rowspan="1" colspan="1">3.58 (0.99)<sup>c</sup></td><td align="center" rowspan="1" colspan="1">3.19 (1.20)<sup>c</sup></td><td align="center" rowspan="1" colspan="1">2.54 (1.21)<sup>c</sup></td><td align="center" rowspan="1" colspan="1">2.27 (1.22)<sup>c</sup></td></tr><tr><td style="background: lightgrey" align="left" rowspan="2" colspan="1">anxiety/somatic<break/>symptoms</td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">experimental </td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">6.77 (1.97) </td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">6.46
(1.84)<sup>b</sup></td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">5.63
(1.90)<sup>c</sup></td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">4.80
(1.88)<sup>c</sup></td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">4.14
(1.68)<sup>c</sup></td><td style="background: lightgrey" align="center" rowspan="2" colspan="1">74.88</td><td style="background: lightgrey" align="center" rowspan="2" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td style="background: lightgrey" align="left" rowspan="1" colspan="1">control</td><td style="background: lightgrey" align="center" rowspan="1" colspan="1"> 6.31 (1.54) </td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">5.88
(1.53)<sup>b</sup></td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">5.19
(1.55)<sup>c</sup></td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">4.58
(1.53)<sup>c</sup></td><td style="background: lightgrey" align="center" rowspan="1" colspan="1">4.31
(1.64)<sup>c</sup></td></tr><tr><td align="left" rowspan="2" colspan="1">weight loss</td><td align="center" rowspan="1" colspan="1">experimental </td><td align="center" rowspan="1" colspan="1">0.86 (0.85)</td><td align="center" rowspan="1" colspan="1"> 0.77 (0.81) </td><td align="center" rowspan="1" colspan="1">0.60 (0.70)<sup>b</sup></td><td align="center" rowspan="1" colspan="1">0.51 (0.61)<sup>c</sup></td><td align="center" rowspan="1" colspan="1">0.43 (0.56)<sup>c</sup></td><td align="center" rowspan="2" colspan="1">18.54</td><td align="center" rowspan="2" colspan="1"><bold>&#x0003c;0.001</bold></td></tr><tr><td align="left" rowspan="1" colspan="1">control</td><td align="center" rowspan="1" colspan="1"> 0.81 (0.80) </td><td align="center" rowspan="1" colspan="1">0.58 (0.70)<sup>b</sup></td><td align="center" rowspan="1" colspan="1">0.58 (0.70)<sup>b</sup></td><td align="center" rowspan="1" colspan="1">0.31 (0.55)<sup>c</sup></td><td align="center" rowspan="1" colspan="1">0.31 (0.47)<sup>c</sup></td></tr></tbody></table><table-wrap-foot><fn><p><sup>a</sup> There was no statistically significant difference
between the two groups on any of the factors at any of the time
points</p><p><sup>b</sup>
<italic>p</italic>&#x0003c;0.05 for one-sample t-test comparison with
baseline score; </p><p><sup>c</sup>
<italic>p</italic>&#x0003c;0.001 for one-sample t-test comparison with
baseline score</p></fn></table-wrap-foot></table-wrap></sec><sec id="s8c"><label>3.3</label><title>Comparison of safety</title><p> No severe adverse events occurred during the trial. Most adverse events occurred
early in the study. There were a total of 15 events in 14 individuals (40%) in
the experiment group: 2 had dry mouth (5.7%), 3 had headaches or discomfort in
the head (8.6%), 2 experienced dizziness (5.7%), 3 had constipation (8.6%), 3
had nausea (8.6%), 1 had excessive sweating (2.9%), and 1 had poor appetite
(2.9%). There were a total of 13 events in 13 individuals (50%) in the control
group: 3 had dry mouth (11.5%), 2 had headaches (7.7%), 4 experienced dizziness
(15.4%), 1 had a stuffy nose (3.85%), 1 had constipation (3.9%), 1 had diarrhea
(3.9%), and 1 had poor appetite (3.9%). All of these adverse events remitted
spontaneously without any treatment; none of them were severe enough to require
discontinuation of the treatment. The proportions of patients in the
experimental and control groups who experienced adverse events were not
statistically significant (40% v. 50%; <italic>&#x003c7;<sup>2</sup></italic>=0.605,
<italic>p</italic>=0.437). </p></sec></sec><sec id="s9"><label>4.</label><title>Discussion</title><sec id="s9a"><label>4.1</label><title>Main findings</title><p> In this double-blind randomized controlled trial that used changes in HAMD-17
total scores as the main outcome measure, we found comparable effectiveness of
the Chinese herbal medicine shuganjieyu with or without adjunctive rTMS in the
inpatient treatment of geriatric depression. Ninety-four percent (61/65) of the
enrolled subjects completed the 6-week trial. None of the patients experienced
serious side effects. Minor side effects occurred in 40% of patients treated
with shuganjie and rTMS (the experimental group) and in 50% of patients treated
with shuganjie and sham rTMS (the control group); all of these side effects
resolved spontaneously and none of them required withdrawal from the study. We
conclude that combined treatment with shuganjieyu and rTMS is safe.</p><p> Improvement in depressive symptoms was progressive over the 6-week trial; by the
end of the 6 weeks the mean overall HAMD-17 score had dropped by 38% in the
experimental group and 37% in the control group. The failure to identify a
significant time by group interaction in the repeated measures ANOVA suggests
that rTMS does not result in a more rapid onset of treatment, as has been
suggested by other authors.<xref rid="B11" ref-type="bibr">[11]</xref> Using a
drop in HAMD-17 score from baseline of 25% or greater as the cutoff for
&#x02018;efficacy&#x02019;, by the end of the trial efficacy was 97% in the experimental group
and 96% in the control group. However, using a drop in the HAMD-17 score from
baseline of 50% or greater as the cutoff for &#x02018;significant improvement&#x02019;, only 20%
(7/35) of the patients in the experimental group and 19% (5/26) of the patients
in the control group had a significant improvement in their depressive symptoms
by the end of the 6 weeks of treatment.</p><p> When considering the five subscales of HAMD-17, there were some minor,
non-significant differences in the onset of the treatment effect between the
different subscales, but all five subscales showed statistically significant
improvement after two weeks of treatment in both treatment groups. </p></sec><sec id="s9b"><label>4.2</label><title>Limitations</title><p> The 97% &#x02018;efficacy&#x02019; of shuganjieyu appears promising but the picture looks quite
different when one realizes that only 20% of patients had a 50% or greater
improvement in their depressive symptoms over the 6-week trial. In the absence
of a full placebo control group or an SSRI comparison group one cannot be
certain that the observed improvement in both groups was the result of
shuganjieyu treatment -- it could have been related to the placebo effect of
being hospitalized. Studies using different types of comparison groups will be
needed to resolve this issue.</p><p> This study was conducted in an inpatient setting with patients who had
relatively severe depressive symptoms. It is unknown whether or not the outcome
would be the same in less-severe, community-based patients. In particular, the
use of rTMS, which required daily sessions at a medical setting over several
weeks, may not be feasible for most community-based patients.</p><p> The failure to find any significant differences between the two groups may be
because we did not use the optimal configuration, frequency, and duration of
rTMS. The optimal parameters may be different in elderly individuals, so
considerable work will be needed to establish standardized methods for
administering rTMS in geriatric depression. Larger studies conducted for longer
periods may identify significant differences when rTMS is used as an adjunctive
treatment for shuganjieyu, but this would probably only be practical in
inpatient settings. There may be specific subgroups of patients for whom rTMS is
a useful adjunctive treatment, but larger studies would be needed to compare
differences between different subgroups of patients to help identify the
subgroups in which rTMS is useful.</p></sec><sec id="s9c"><label>4.3</label><title>Implications</title><p> We confirm the efficacy and safety of the Chinese herbal medicine shuganjieyu in
the treatment of geriatric depression. However, after 6 weeks of treatment only
20% of the subjects had a significant improvement in their depressive symptoms
(defined as a 50% drop in the baseline HAMD-17 score) so the value of this
medicine as a first-line treatment for geriatric depression may be limited.
Shuganjieyu may, however, be useful as a second-line treatment for elderly
individuals who cannot tolerate SSRIs. We did not find that adjunctive treatment
with rTMS improved overall outcomes for shuganjieuyu or resulted in a more rapid
onset of action, though larger samples and longer follow-up studies may be
needed to definitively address this issue. </p></sec></sec></body><back><fn-group><fn><p>Conflict of interest: The authors declare no conflict of interest.</p></fn></fn-group><fn-group><fn><p>Ethics approval: This study was approved by the ethics committee of Daqing Third
Hospital. </p></fn></fn-group><fn-group><fn><p>Informed consent: All participants or their guardians provided informed consent
to participate in this study.</p></fn></fn-group><bio id="d35e38"><p><graphic xlink:href="sap-27-02-103-g001.gif" position="float" orientation="portrait"/></p><p>Minmin Xie obtained her bachelor&#x02019;s degree in medicine from Harbin Medical
University (Daqing Campus) in June 2013. She enrolled in a master&#x02019;s
program at Harbin Medical University (Daqing Campus) in 2013 and is
currently doing her internship at the Geriatrics Department of the Third
Hospital of Daqing. Her research interest is the treatment of geriatric
mental disorders. </p></bio><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lingworth</surname><given-names>SA</given-names></name><name><surname>Burgess</surname><given-names>PM</given-names></name><name><surname>Whiteford</surname><given-names>HA</given-names></name></person-group><article-title>Affective and anxiety disorders: prevalence, treatment and
antidepressant medication use</article-title><source>Aust N Z J Psychiatry</source><year>2010</year><volume>44</volume><issue>6</issue><fpage> 513</fpage><lpage>519</lpage><pub-id pub-id-type="pmid">20482411</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Clignet</surname><given-names>F</given-names></name><name><surname>van</surname><given-names>Meijel B</given-names></name><name><surname>vail</surname><given-names>Straten A</given-names></name><name><surname>Cuijpers</surname><given-names>P</given-names></name></person-group><article-title>The systematic activation method as a nursing intervention in
depressed elderly: a protocol for a multi-centre cluster randomized
trial</article-title><source>BMC Psychiatry</source><year>2012</year><volume>12</volume><issue>1</issue><fpage>144</fpage><pub-id pub-id-type="doi">10.1186/1471-244X-12-144</pub-id><pub-id pub-id-type="pmid">22989021</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>[Efficacy observation of the sertraline treatment combined with
Shuganjieyu capsule on the elderly patients with depression]</article-title><source>Zhongguo Yi Yao Zhi Nan</source><year>2013</year><volume>11</volume><issue>34</issue><fpage> 495</fpage><lpage>496</lpage><comment>Chinese</comment></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Digby</surname><given-names>G</given-names></name><name><surname>Machaalany</surname><given-names>J</given-names></name><name><surname>Malik</surname><given-names>P</given-names></name><name><surname>Methot</surname><given-names>M</given-names></name><name><surname>Simpson</surname><given-names>CS</given-names></name><name><surname>Redfearn</surname><given-names>D</given-names></name><etal/></person-group><article-title>Multifactorial QT interval prolongation</article-title><source>Cardiol J</source><year>2010</year><volume>17</volume><issue>2</issue><fpage> 184</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">20544619</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>SB</given-names></name><name><surname>Li</surname><given-names>CF</given-names></name><name><surname>Wang</surname><given-names>YF</given-names></name><name><surname>Li</surname><given-names>J</given-names></name></person-group><article-title>[Case-control study of the treatment of Shuganjieyu capsule
combined with venlafaxine on the elderly patients with
depression]</article-title><source>Lin Chuang Jing Shen Yi Xue Za Zhi</source><year>2012</year><volume>22</volume><issue>2</issue><fpage> 98. Chinese</fpage></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>JD</given-names></name><name><surname>Chen</surname><given-names>YX</given-names></name><name><surname>Huang</surname><given-names>SP</given-names></name></person-group><article-title>[The efficacy of Shuganjieyu capsule combined with venlafaxine in
treatment of senile depression]</article-title><source>Yi Xue Zong Shu</source><year>2013</year><volume>19</volume><issue>17</issue><fpage> 2302</fpage><lpage>2308</lpage><comment>Chinese</comment><pub-id pub-id-type="doi">10.3969/j.issn.1006-2084.2013.17.043</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Alexopoulos</surname><given-names>GS</given-names></name><name><surname>Kelly</surname><given-names>RE</given-names></name></person-group><article-title>Research advances in geriatric depression</article-title><source>World Psychiatry</source><year>2009</year><volume>8</volume><issue>3</issue><fpage> 140</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">19812743</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Russo</surname><given-names>E</given-names></name><name><surname>Scicchitano</surname><given-names>F</given-names></name><name><surname>Whalley</surname><given-names>BJ</given-names></name><name><surname>Mazzitello</surname><given-names>C</given-names></name><name><surname>Ciriaco</surname><given-names>M</given-names></name><name><surname>Esposito</surname><given-names>S</given-names></name><etal/></person-group><article-title> Hypericumperforatum: pharmacokinetic, mechanism of action,
tolerability, and clinical drug-drug interactions</article-title><source>Phytother Res</source><year>2014</year><volume>28</volume><issue>5</issue><fpage>643</fpage><lpage>655</lpage><pub-id pub-id-type="doi">10.1002/ptr.5050</pub-id><pub-id pub-id-type="pmid">23897801</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dumas</surname><given-names>R</given-names></name><name><surname>Padovani</surname><given-names>R</given-names></name><name><surname>Richierij</surname><given-names>R</given-names></name><name><surname>Lan&#x000e7;on</surname><given-names>C</given-names></name></person-group><article-title>[Repetitive transcranial magnetic stimulation in major
depression: response factor]</article-title><source>Encephale</source><year>2012</year><volume>38</volume><issue>4</issue><fpage> 360</fpage><lpage>368. French</lpage><pub-id pub-id-type="doi">10.1016/j.encep.2011.08.004</pub-id><pub-id pub-id-type="pmid">22980479</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richieri</surname><given-names>R</given-names></name><name><surname>Guedj</surname><given-names>E</given-names></name><name><surname>Michel</surname><given-names>P</given-names></name><name><surname>Lan&#x000e7;on</surname><given-names>C</given-names></name><name><surname>Boyer</surname><given-names>L</given-names></name></person-group><article-title>Maintenance transcranial magnetic stimulation reduces depression
relapse: a propensity-adjusted analysis</article-title><source>J Affect Disord</source><year>2013</year><volume>151</volume><issue>1</issue><fpage> 129</fpage><lpage>135.</lpage><pub-id pub-id-type="doi">10.1016/j.jad.2013.05.062</pub-id><pub-id pub-id-type="pmid">23790811</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schutter</surname><given-names>DJ</given-names></name></person-group><article-title>Quantitative review of the efficacy of slowfrequency magnetic
brain stimulation in major depressive disorder</article-title><source>Psychol Med</source><year>2010</year><volume>40</volume><issue>11</issue><fpage> 1789</fpage><lpage>1795</lpage><pub-id pub-id-type="pmid">20102670</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="book" publication-format="web"><collab>World Health Organization</collab><source>ICD-10 Classifications of Mental and Behavioural Disorder: Clinical
Descriptions and Diagnostic Guidelines</source><publisher-loc>Geneva</publisher-loc><publisher-name>World Health Organization</publisher-name><year>1992</year></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>HT</given-names></name><name><surname>Han</surname><given-names>G</given-names></name><name><surname>Zhu</surname><given-names>XC</given-names></name><name><surname>Guo</surname><given-names>RJ</given-names></name></person-group><article-title>[Progress on depression due to liver stagnation and spleen
deficiency: a literature review]</article-title><source>Huan Qiu Zhong Yi Yao</source><year>2014</year><volume>7</volume><issue>2</issue><fpage> 46</fpage><lpage>50</lpage><comment>Chinese</comment><pub-id pub-id-type="doi">10.3969/j.issn.1674-1749.2014.02.022</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>MY</given-names></name></person-group><source>[Manual of Psychiatric Rating Scale]</source><collab>Hunan Science and Technology Press</collab><publisher-loc>Changsha</publisher-loc><publisher-name>Hunan Science and Technology Press</publisher-name><year>121</year><fpage>204</fpage></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dan</surname><given-names>B</given-names></name></person-group><article-title>[Assessment on diagnosis and efficacy of Han Mitton Depression
Scale for 136 cases of post-stroke depression]</article-title><source>Zhongguo Wu Zhen Xue Za Zhi</source><year>2007</year><volume>7</volume><issue>24</issue><fpage> 5848</fpage><lpage>5849</lpage><comment>Chinese</comment><pub-id pub-id-type="doi">10.3969/j.issn.1009-6647.2007.24.129</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YY</given-names></name><name><surname>Wang</surname><given-names>YJ</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name></person-group><article-title>[The effects on the score of the each factor of HAMD for mild to
moderate depression treated with abdominal acupuncture]</article-title><source>Liao Ning Zhong Yi Za Zhi</source><year>2011</year><volume>38</volume><issue>5</issue><fpage> 981</fpage><lpage>983</lpage><comment>Chinese</comment></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="book"><source>[Clinical and neuroimaging studies of depression in elderly].</source><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JD</given-names></name></person-group><publisher-loc>Hu Nan, Changsha:</publisher-loc><publisher-name>Central South University</publisher-name><year>2008</year><comment>Chinese</comment></element-citation></ref></ref-list></back></article>